BIT biotron limited

0.00%

0.2¢

Back to university research labs for this lot whether they get...

First 108 Last

Share
Profile

Follow
il duce

707 Posts.

145

07/11/24

10:46

Post #: 76495609
Share

Originally posted by WelshBuffett: ↑

There is strong support for the price between 1.6c and 1.9c. This is a historical support level. I think it stays above these levels in the short term( unless there is a significant discount on the SP for a CR.

The "wipeout" has already occurred. If this company was truly a phase 2(b) HIV success, then the market cap should be above $200 million, maybe more. Why is it discounted soo heavily?

I think the answer =2018, specifically towards the end of that year. The company presented the original phase two trial as a breakthrough for HIV, bit225 eradicating the virus in the reservoirs etc

They also told punters over the phone and at the AGM that they were negotiating a deal and it sounded like it was close to a done deal. A few posters recorded JJ and gilead, as the two parties in the mix. So if any of this is true, then why no deals seven years later? I find interesting that whilst they remarkable results were published and the company was negotiating a potential deal, the directors sold nearly a million bucks worth of shares at 20-18c. There are a number of reasons why they could sell. Tax bills etc; but the timing just doesn't make sense, if the results were remarkable and a potential commercial deal was being negotiated .

Roll onto 2024.... couple of quarters of cash left. No deal. Most investors know that the options are dead, which is a real shame as it would have given the company a chance to look at cancer or zika. They can still look at these areas (again), but will need some $$$.

The big problem is the patent expiry. The clock is ticking down. They've got lots of interesting ideas, but not a lot of time on the clock.

Expand

Back to university research labs for this lot whether they get to play with taxpayers money to their hearts content until the government wakes up to the scam and sacks them for good.

BIT Price at posting: 2.1¢ Sentiment: Sell Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

First 108 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $2.654M

Open	High	Low	Value	Volume
0.2¢	0.2¢	0.2¢	$210	104.8K

Buyers (Bids)

No.	Vol.	Price($)
64	38848316	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	18281126	25

View Market Depth

No.	Vol.	Price($)
59	37148316	0.002
33	65631001	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	14162401	23
0.004	12820969	17
0.005	6684000	5
0.006	1200000	2
0.007	1084188	2

Last trade - 12.28pm 27/06/2025 (20 minute delay)

BIT (ASX) Chart

Back to university research labs for this lot whether they get...

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Monash IVF shares cater 25% – Disaster or deep-value play?

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Back to university research labs for this lot whether they get...

Top Stories

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Monash IVF shares cater 25% – Disaster or deep-value play?

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News